Vaxcyte Inc's stock experienced a remarkable surge, driven by positive clinical trial results and investor enthusiasm in the vaccine sector.
Vaxcyte Inc (NASDAQ:PCVX) saw its shares soar by 30.70% in yesterday's trading session, closing at CA$73.82. This significant jump was largely attributed to the company's recent clinical milestone announcement regarding its pneumococcal conjugate vaccine candidate, VAX-31.
Advertisement
Vaxcyte Inc
PCVX.US
PCVX.US
Vaxcyte Inc
WealthAwesomeMarket cap
$8.40B
52W high
$90.75
52W low
$39.87
1W change
+26.69%
Beta
1.22
Analyst Price Targets
Based on 11 analysts covering PCVX · as of Oct 5, 2026
Wall Street analysts forecast PCVX stock price to rise 47.2% over the next 12 months.
Consensus
Strong Buy4.73 / 5.00
Avg. Target
C$108.67
+47.2% Upside
Current Price
C$73.82
Last close
Analyst Breakdown (11 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PCVX's historical volatility
30-Day Vol
83.1%
Annualized
90-Day Vol
62.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$88.25
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$78.35 | C$58.82 – C$104.36 |
| 60 trading days | C$83.15 | C$55.44 – C$124.73 |
| 90 trading days | C$88.25 | C$53.71 – C$145.01 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are optimistic about Vaxcyte's future potential following the successful Phase 3 trial results, which could pave the way for commercial success and increased market share in the vaccine industry.
Vaxcyte's stock jumped 30.70% yesterday.
This surge reflects strong investor confidence following positive clinical trial results, indicating a potential shift in market perception of the company's future prospects.
Bull case
The successful Phase 3 trial results for VAX-31 not only exceeded expectations but also positioned Vaxcyte as a key player in the vaccine market. This could lead to significant revenue growth as the product moves closer to commercialization.
Bear case
Despite the positive trial results, some investors are worried about the impact of the recent $1 billion capital raise, which might dilute shareholder value in the short term.
Clinical Milestone Drives Stock Surge
Advertisement
Vaxcyte announced that its VAX-31 vaccine candidate met all prespecified co-primary immunogenicity endpoints in the pivotal adult OPUS-1 Phase 3 trial. This success not only exceeded management's expectations but also reinvigorated investor interest in the company's potential to capture market share in the vaccine sector.
Investor Sentiment and Market Reaction
Following the announcement, Vaxcyte's stock saw a significant uptick, reflecting heightened investor confidence. The positive results from the clinical trial have positioned Vaxcyte favorably in the eyes of investors, suggesting a potential for robust revenue growth as the company prepares for the commercialization of its vaccine.
Concerns Over Capital Raise
Despite the positive news, Vaxcyte's recent announcement of a $1 billion capital raise raised some concerns among investors regarding potential dilution of shares. The company aims to use the proceeds to fund clinical development and manufacturing scale-up, which could impact short-term shareholder value.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
